ID   GATA2_HUMAN             Reviewed;         480 AA.
AC   P23769; D3DNB3; Q53YE0; Q96BH0; Q96BH8; Q9BUJ6;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   07-APR-2021, entry version 195.
DE   RecName: Full=Endothelial transcription factor GATA-2;
DE   AltName: Full=GATA-binding protein 2;
GN   Name=GATA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1714909;
RA   Lee M.-E., Temizer D.T., Clifford J.A., Quertermous T.;
RT   "Cloning of the GATA-binding protein that regulates endothelin-1 gene
RT   expression in endothelial cells.";
RL   J. Biol. Chem. 266:16188-16192(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Endothelial cell;
RX   PubMed=1370462;
RA   Dorfman D.M., Wilson D.B., Bruns G.A.P., Orkin S.H.;
RT   "Human transcription factor GATA-2. Evidence for regulation of
RT   preproendothelin-1 gene expression in endothelial cells.";
RL   J. Biol. Chem. 267:1279-1285(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-164.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-164.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   THR-164.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-73 AND SER-192, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   INTERACTION WITH AR AND CCAR1.
RX   PubMed=23887938; DOI=10.1093/nar/gkt644;
RA   Seo W.Y., Jeong B.C., Yu E.J., Kim H.J., Kim S.H., Lim J.E., Kwon G.Y.,
RA   Lee H.M., Kim J.H.;
RT   "CCAR1 promotes chromatin loading of androgen receptor (AR) transcription
RT   complex by stabilizing the association between AR and GATA2.";
RL   Nucleic Acids Res. 41:8526-8536(2013).
RN   [10]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-86, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [11]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-389, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [12]
RP   VARIANTS IMD21 LEU-254; MET-354 AND TRP-398.
RX   PubMed=21670465; DOI=10.1182/blood-2011-05-356352;
RA   Hsu A.P., Sampaio E.P., Khan J., Calvo K.R., Lemieux J.E., Patel S.Y.,
RA   Frucht D.M., Vinh D.C., Auth R.D., Freeman A.F., Olivier K.N., Uzel G.,
RA   Zerbe C.S., Spalding C., Pittaluga S., Raffeld M., Kuhns D.B., Ding L.,
RA   Paulson M.L., Marciano B.E., Gea-Banacloche J.C., Orange J.S.,
RA   Cuellar-Rodriguez J., Hickstein D.D., Holland S.M.;
RT   "Mutations in GATA2 are associated with the autosomal dominant and sporadic
RT   monocytopenia and mycobacterial infection (MonoMAC) syndrome.";
RL   Blood 118:2653-2655(2011).
RN   [13]
RP   VARIANTS LMPM PRO-361 AND ARG-373.
RX   PubMed=21892158; DOI=10.1038/ng.923;
RA   Ostergaard P., Simpson M.A., Connell F.C., Steward C.G., Brice G.,
RA   Woollard W.J., Dafou D., Kilo T., Smithson S., Lunt P., Murday V.A.,
RA   Hodgson S., Keenan R., Pilz D.T., Martinez-Corral I., Makinen T.,
RA   Mortimer P.S., Jeffery S., Trembath R.C., Mansour S.;
RT   "Mutations in GATA2 cause primary lymphedema associated with a
RT   predisposition to acute myeloid leukemia (Emberger syndrome).";
RL   Nat. Genet. 43:929-931(2011).
RN   [14]
RP   VARIANTS MDS MET-354 AND THR-355 DEL.
RX   PubMed=21892162; DOI=10.1038/ng.913;
RA   Hahn C.N., Chong C.E., Carmichael C.L., Wilkins E.J., Brautigan P.J.,
RA   Li X.C., Babic M., Lin M., Carmagnac A., Lee Y.K., Kok C.H., Gagliardi L.,
RA   Friend K.L., Ekert P.G., Butcher C.M., Brown A.L., Lewis I.D., To L.B.,
RA   Timms A.E., Storek J., Moore S., Altree M., Escher R., Bardy P.G.,
RA   Suthers G.K., D'Andrea R.J., Horwitz M.S., Scott H.S.;
RT   "Heritable GATA2 mutations associated with familial myelodysplastic
RT   syndrome and acute myeloid leukemia.";
RL   Nat. Genet. 43:1012-1017(2011).
CC   -!- FUNCTION: Transcriptional activator which regulates endothelin-1 gene
CC       expression in endothelial cells. Binds to the consensus sequence 5'-
CC       AGATAG-3'.
CC   -!- SUBUNIT: Interacts with BRD3 (By similarity). Interacts with AR and
CC       CCAR1. {ECO:0000250|UniProtKB:O09100, ECO:0000269|PubMed:23887938}.
CC   -!- INTERACTION:
CC       P23769; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-2806671, EBI-10173507;
CC       P23769; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-2806671, EBI-3867333;
CC       P23769; Q13643: FHL3; NbExp=5; IntAct=EBI-2806671, EBI-741101;
CC       P23769; Q08379: GOLGA2; NbExp=4; IntAct=EBI-2806671, EBI-618309;
CC       P23769; Q6A162: KRT40; NbExp=3; IntAct=EBI-2806671, EBI-10171697;
CC       P23769; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-2806671, EBI-10172052;
CC       P23769; Q8IUC1: KRTAP11-1; NbExp=3; IntAct=EBI-2806671, EBI-1052037;
CC       P23769; Q3SY46: KRTAP13-3; NbExp=3; IntAct=EBI-2806671, EBI-10241252;
CC       P23769; Q3LI59: KRTAP21-2; NbExp=3; IntAct=EBI-2806671, EBI-18395721;
CC       P23769; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-2806671, EBI-9996449;
CC       P23769; Q8IUC3: KRTAP7-1; NbExp=3; IntAct=EBI-2806671, EBI-18394498;
CC       P23769; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-2806671, EBI-10261141;
CC       P23769; Q99750: MDFI; NbExp=4; IntAct=EBI-2806671, EBI-724076;
CC       P23769; P35548: MSX2; NbExp=3; IntAct=EBI-2806671, EBI-6447480;
CC       P23769; Q7Z3S9: NOTCH2NLA; NbExp=4; IntAct=EBI-2806671, EBI-945833;
CC       P23769; P86479: PRR20C; NbExp=3; IntAct=EBI-2806671, EBI-10172814;
CC       P23769; P25788: PSMA3; NbExp=4; IntAct=EBI-2806671, EBI-348380;
CC       P23769; Q93062-3: RBPMS; NbExp=3; IntAct=EBI-2806671, EBI-740343;
CC       P23769; Q13485: SMAD4; NbExp=2; IntAct=EBI-2806671, EBI-347263;
CC       P23769; P17947: SPI1; NbExp=4; IntAct=EBI-2806671, EBI-2293548;
CC       P23769; Q13077: TRAF1; NbExp=3; IntAct=EBI-2806671, EBI-359224;
CC       P23769; P36406: TRIM23; NbExp=4; IntAct=EBI-2806671, EBI-740098;
CC       P23769; P25801: Lmo2; Xeno; NbExp=3; IntAct=EBI-2806671, EBI-3903256;
CC       P23769-2; P28329-3: CHAT; NbExp=3; IntAct=EBI-21856389, EBI-25837549;
CC       P23769-2; P22607: FGFR3; NbExp=3; IntAct=EBI-21856389, EBI-348399;
CC       P23769-2; P28799: GRN; NbExp=3; IntAct=EBI-21856389, EBI-747754;
CC       P23769-2; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-21856389, EBI-396669;
CC       P23769-2; O76024: WFS1; NbExp=3; IntAct=EBI-21856389, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P23769-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P23769-2; Sequence=VSP_041126;
CC   -!- TISSUE SPECIFICITY: Endothelial cells.
CC   -!- DISEASE: Immunodeficiency 21 (IMD21) [MIM:614172]: An immunodeficiency
CC       disease characterized by profoundly decreased or absent monocytes, B-
CC       lymphocytes, natural killer lymphocytes, and circulating and tissue
CC       dendritic cells, with little or no effect on T-cell numbers. Clinical
CC       features of DCML include susceptibility to disseminated non-tuberculous
CC       mycobacterial infections, papillomavirus infections, opportunistic
CC       fungal infections, and pulmonary alveolar proteinosis. Bone marrow
CC       hypocellularity and dysplasia of myeloid, erythroid, and megakaryocytic
CC       lineages are present in most patients, as are karyotypic abnormalities,
CC       including monosomy 7 and trisomy 8. This syndrome links susceptibility
CC       to mycobacterial, viral, and fungal infections with malignancy and can
CC       be transmitted in an autosomal dominant pattern.
CC       {ECO:0000269|PubMed:21670465}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Lymphedema, primary, with myelodysplasia (LMPM) [MIM:614038]:
CC       A chronic disabling condition characterized by swelling of the
CC       extremities due to altered lymphatic flow, associated with
CC       myelodysplasia. Patients with lymphedema suffer from recurrent local
CC       infections, and physical impairment. {ECO:0000269|PubMed:21892158}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Myelodysplastic syndrome (MDS) [MIM:614286]: A heterogeneous
CC       group of closely related clonal hematopoietic disorders. All are
CC       characterized by a hypercellular or hypocellular bone marrow with
CC       impaired morphology and maturation, dysplasia of the myeloid,
CC       megakaryocytic and/or erythroid lineages, and peripheral blood
CC       cytopenias resulting from ineffective blood cell production. Included
CC       diseases are: refractory anemia (RA), refractory anemia with ringed
CC       sideroblasts (RARS), refractory anemia with excess blasts (RAEB),
CC       refractory cytopenia with multilineage dysplasia and ringed
CC       sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a
CC       myelodysplastic/myeloproliferative disease. MDS is considered a
CC       premalignant condition in a subgroup of patients that often progresses
CC       to acute myeloid leukemia (AML). {ECO:0000269|PubMed:21892162}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35869.1; Type=Miscellaneous discrepancy; Note=Several sequencing errors.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GATA2ID44160ch3q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M68891; AAA35868.1; -; mRNA.
DR   EMBL; M77810; AAA35869.1; ALT_SEQ; mRNA.
DR   EMBL; BT006671; AAP35317.1; -; mRNA.
DR   EMBL; AK314826; BAG37347.1; -; mRNA.
DR   EMBL; AC080005; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79313.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79314.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79315.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79316.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79317.1; -; Genomic_DNA.
DR   EMBL; BC002557; AAH02557.1; -; mRNA.
DR   EMBL; BC015613; AAH15613.1; -; mRNA.
DR   EMBL; BC015577; AAH15577.1; -; mRNA.
DR   EMBL; BC018988; AAH18988.1; -; mRNA.
DR   EMBL; BC051272; AAH51272.1; -; mRNA.
DR   EMBL; BC051342; AAH51342.1; -; mRNA.
DR   CCDS; CCDS3049.1; -. [P23769-1]
DR   CCDS; CCDS46903.1; -. [P23769-2]
DR   PIR; A40815; A40815.
DR   PIR; A41782; A41782.
DR   RefSeq; NP_001139133.1; NM_001145661.1. [P23769-1]
DR   RefSeq; NP_001139134.1; NM_001145662.1. [P23769-2]
DR   RefSeq; NP_116027.2; NM_032638.4. [P23769-1]
DR   PDB; 5O9B; NMR; -; A=343-391.
DR   PDBsum; 5O9B; -.
DR   SMR; P23769; -.
DR   BioGRID; 108894; 60.
DR   DIP; DIP-29711N; -.
DR   IntAct; P23769; 40.
DR   STRING; 9606.ENSP00000345681; -.
DR   iPTMnet; P23769; -.
DR   PhosphoSitePlus; P23769; -.
DR   BioMuta; GATA2; -.
DR   DMDM; 229462971; -.
DR   EPD; P23769; -.
DR   jPOST; P23769; -.
DR   MassIVE; P23769; -.
DR   MaxQB; P23769; -.
DR   PaxDb; P23769; -.
DR   PeptideAtlas; P23769; -.
DR   PRIDE; P23769; -.
DR   ProteomicsDB; 54160; -. [P23769-1]
DR   ProteomicsDB; 54161; -. [P23769-2]
DR   Antibodypedia; 788; 479 antibodies.
DR   DNASU; 2624; -.
DR   Ensembl; ENST00000341105; ENSP00000345681; ENSG00000179348. [P23769-1]
DR   Ensembl; ENST00000430265; ENSP00000400259; ENSG00000179348. [P23769-2]
DR   Ensembl; ENST00000487848; ENSP00000417074; ENSG00000179348. [P23769-1]
DR   GeneID; 2624; -.
DR   KEGG; hsa:2624; -.
DR   UCSC; uc003ekm.4; human. [P23769-1]
DR   CTD; 2624; -.
DR   DisGeNET; 2624; -.
DR   GeneCards; GATA2; -.
DR   HGNC; HGNC:4171; GATA2.
DR   HPA; ENSG00000179348; Tissue enhanced (blood, ductus deferens, seminal vesicle).
DR   MalaCards; GATA2; -.
DR   MIM; 137295; gene.
DR   MIM; 614038; phenotype.
DR   MIM; 614172; phenotype.
DR   MIM; 614286; phenotype.
DR   neXtProt; NX_P23769; -.
DR   OpenTargets; ENSG00000179348; -.
DR   Orphanet; 3226; Deafness-lymphedema-leukemia syndrome.
DR   Orphanet; 319465; Inherited acute myeloid leukemia.
DR   Orphanet; 228423; Monocytopenia with susceptibility to infections.
DR   Orphanet; 52688; Myelodysplastic syndrome.
DR   PharmGKB; PA28585; -.
DR   VEuPathDB; HostDB:ENSG00000179348.11; -.
DR   eggNOG; KOG1601; Eukaryota.
DR   GeneTree; ENSGT00940000156315; -.
DR   HOGENOM; CLU_027524_1_0_1; -.
DR   InParanoid; P23769; -.
DR   OMA; SHMAHMG; -.
DR   OrthoDB; 1240204at2759; -.
DR   PhylomeDB; P23769; -.
DR   TreeFam; TF315391; -.
DR   PathwayCommons; P23769; -.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P23769; -.
DR   SIGNOR; P23769; -.
DR   BioGRID-ORCS; 2624; 27 hits in 1026 CRISPR screens.
DR   ChiTaRS; GATA2; human.
DR   GeneWiki; GATA2; -.
DR   GenomeRNAi; 2624; -.
DR   Pharos; P23769; Tbio.
DR   PRO; PR:P23769; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P23769; protein.
DR   Bgee; ENSG00000179348; Expressed in endometrium and 233 other tissues.
DR   ExpressionAtlas; P23769; baseline and differential.
DR   Genevisible; P23769; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005667; C:transcription regulator complex; IEA:Ensembl.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:BHF-UCL.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0021533; P:cell differentiation in hindbrain; IEA:Ensembl.
DR   GO; GO:0045165; P:cell fate commitment; IBA:GO_Central.
DR   GO; GO:0001709; P:cell fate determination; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0021954; P:central nervous system neuron development; IEA:Ensembl.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0021902; P:commitment of neuronal cell to specific neuron type in forebrain; IEA:Ensembl.
DR   GO; GO:0060216; P:definitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0035854; P:eosinophil fate commitment; IDA:BHF-UCL.
DR   GO; GO:0097154; P:GABAergic neuron differentiation; IEA:Ensembl.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:0070345; P:negative regulation of fat cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0045650; P:negative regulation of macrophage differentiation; IEA:Ensembl.
DR   GO; GO:2000178; P:negative regulation of neural precursor cell proliferation; IDA:MGI.
DR   GO; GO:0045746; P:negative regulation of Notch signaling pathway; IDA:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:MGI.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:1903589; P:positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0043306; P:positive regulation of mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0045654; P:positive regulation of megakaryocyte differentiation; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; ISS:UniProtKB.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IEA:Ensembl.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:2000977; P:regulation of forebrain neuron differentiation; IEA:Ensembl.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0035065; P:regulation of histone acetylation; IEA:Ensembl.
DR   GO; GO:0010725; P:regulation of primitive erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0033993; P:response to lipid; IEA:Ensembl.
DR   GO; GO:0060872; P:semicircular canal development; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0001655; P:urogenital system development; IEA:Ensembl.
DR   GO; GO:0061042; P:vascular wound healing; IMP:BHF-UCL.
DR   GO; GO:0021514; P:ventral spinal cord interneuron differentiation; IEA:Ensembl.
DR   CDD; cd00202; ZnF_GATA; 2.
DR   Gene3D; 3.30.50.10; -; 2.
DR   InterPro; IPR029522; GATA-2.
DR   InterPro; IPR016374; TF_GATA-2/3.
DR   InterPro; IPR039355; Transcription_factor_GATA.
DR   InterPro; IPR000679; Znf_GATA.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR10071; PTHR10071; 1.
DR   PANTHER; PTHR10071:SF149; PTHR10071:SF149; 1.
DR   Pfam; PF00320; GATA; 2.
DR   PIRSF; PIRSF003027; TF_GATA-1/2/3; 1.
DR   PRINTS; PR00619; GATAZNFINGER.
DR   SMART; SM00401; ZnF_GATA; 2.
DR   PROSITE; PS00344; GATA_ZN_FINGER_1; 2.
DR   PROSITE; PS50114; GATA_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Disease variant;
KW   DNA-binding; Isopeptide bond; Metal-binding; Methylation; Nucleus;
KW   Phagocytosis; Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..480
FT                   /note="Endothelial transcription factor GATA-2"
FT                   /id="PRO_0000083403"
FT   ZN_FING         295..319
FT                   /note="GATA-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   ZN_FING         349..373
FT                   /note="GATA-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   MOD_RES         73
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         86
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         192
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        389
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         340..353
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041126"
FT   VARIANT         164
FT                   /note="A -> T (in dbSNP:rs2335052)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT                   /id="VAR_055004"
FT   VARIANT         235
FT                   /note="T -> N (in dbSNP:rs35079193)"
FT                   /id="VAR_055005"
FT   VARIANT         254
FT                   /note="P -> L (in IMD21; dbSNP:rs387906630)"
FT                   /evidence="ECO:0000269|PubMed:21670465"
FT                   /id="VAR_066405"
FT   VARIANT         354
FT                   /note="T -> M (in IMD21 and MDS; dbSNP:rs387906631)"
FT                   /evidence="ECO:0000269|PubMed:21670465,
FT                   ECO:0000269|PubMed:21892162"
FT                   /id="VAR_066406"
FT   VARIANT         355
FT                   /note="Missing (in MDS)"
FT                   /evidence="ECO:0000269|PubMed:21892162"
FT                   /id="VAR_066643"
FT   VARIANT         361
FT                   /note="R -> P (in LMPM)"
FT                   /evidence="ECO:0000269|PubMed:21892158"
FT                   /id="VAR_066644"
FT   VARIANT         373
FT                   /note="C -> R (in LMPM; dbSNP:rs387906633)"
FT                   /evidence="ECO:0000269|PubMed:21892158"
FT                   /id="VAR_066645"
FT   VARIANT         398
FT                   /note="R -> W (in IMD21; dbSNP:rs387906629)"
FT                   /evidence="ECO:0000269|PubMed:21670465"
FT                   /id="VAR_066407"
FT   CONFLICT        9
FT                   /note="R -> G (in Ref. 1; AAA35868)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        20..21
FT                   /note="QH -> HD (in Ref. 1; AAA35868)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        38..39
FT                   /note="QL -> HV (in Ref. 1; AAA35868)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69
FT                   /note="R -> A (in Ref. 1; AAA35868)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        82
FT                   /note="G -> S (in Ref. 1; AAA35868)"
FT                   /evidence="ECO:0000305"
FT   TURN            350..352
FT                   /evidence="ECO:0007744|PDB:5O9B"
FT   HELIX           371..380
FT                   /evidence="ECO:0007744|PDB:5O9B"
FT   STRAND          386..389
FT                   /evidence="ECO:0007744|PDB:5O9B"
SQ   SEQUENCE   480 AA;  50500 MW;  C879CC932C355E6A CRC64;
     MEVAPEQPRW MAHPAVLNAQ HPDSHHPGLA HNYMEPAQLL PPDEVDVFFN HLDSQGNPYY
     ANPAHARARV SYSPAHARLT GGQMCRPHLL HSPGLPWLDG GKAALSAAAA HHHNPWTVSP
     FSKTPLHPSA AGGPGGPLSV YPGAGGGSGG GSGSSVASLT PTAAHSGSHL FGFPPTPPKE
     VSPDPSTTGA ASPASSSAGG SAARGEDKDG VKYQVSLTES MKMESGSPLR PGLATMGTQP
     ATHHPIPTYP SYVPAAAHDY SSGLFHPGGF LGGPASSFTP KQRSKARSCS EGRECVNCGA
     TATPLWRRDG TGHYLCNACG LYHKMNGQNR PLIKPKRRLS AARRAGTCCA NCQTTTTTLW
     RRNANGDPVC NACGLYYKLH NVNRPLTMKK EGIQTRNRKM SNKSKKSKKG AECFEELSKC
     MQEKSSPFSA AALAGHMAPV GHLPPFSHSG HILPTPTPIH PSSSLSFGHP HPSSMVTAMG
//
